ABVC BioPharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 2836 www.abvcpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC BioPharma, Inc.

ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - Aug 15th, 2024 11:30 am
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI - Jul 9th, 2024 11:16 am
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals - Jul 2nd, 2024 1:00 pm
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market - Jun 25th, 2024 1:00 pm
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue - Jun 12th, 2024 1:20 pm
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M - May 24th, 2024 1:00 pm
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M - May 22nd, 2024 1:00 pm
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M - May 15th, 2024 1:25 pm
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - May 9th, 2024 1:35 pm
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - Apr 18th, 2024 1:25 pm
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - Apr 17th, 2024 1:00 pm
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - Apr 10th, 2024 12:36 pm
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - Mar 26th, 2024 12:35 pm
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars - Mar 21st, 2024 12:30 pm
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - Mar 19th, 2024 12:34 pm
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update - Mar 14th, 2024 1:34 pm
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars - Feb 27th, 2024 1:30 pm
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues - Feb 15th, 2024 1:30 pm
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) - Feb 12th, 2024 1:30 pm
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share - Feb 8th, 2024 2:22 pm